Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

06 Jun 2016 - 09 Jun 2016
22 Jun 2016 - 24 Jun 2016
04 Jul 2016 - 06 Jul 2016

New Approach Restores Effectiveness of Older Antibiotics

By BiotechDaily International staff writers
Posted on 29 Apr 2014
Print article
Image: Cultured bacteria showing increased sensitivity to antibiotics with the additional of a metallopolymer (Photo courtesy of University of South Carolina).
Image: Cultured bacteria showing increased sensitivity to antibiotics with the additional of a metallopolymer (Photo courtesy of University of South Carolina).
Methicillin-resistant Staphylococcus aureus (MRSA), a complex of multidrug-resistant Gram-positive bacterial strains, has proven especially problematic in both hospital and community settings.

These bacteria have become drug resistant by deactivating conventional β-lactam antibiotics, including penicillins, cephalosporins, and carbapenems.

Microbiologists at the University of South Carolina (Columbia, SC, USA) introduced a class of charged metallopolymers that exhibit synergistic effects against MRSA by efficiently inhibiting activity of β-lactamase and effectively lysing bacterial cells.

The β-lactam structure in a molecule is something that many bacteria are adverse to. It greatly hinders their ability to reproduce by cell division, and so chemists have for years spent time making molecules that all contain the β-lactam structural motif. One of the most effective bacterial defenses is an enzyme called β-lactamase, which chews up the β-lactam structure. Some bacteria, such as MRSA, have developed the ability to biosynthesize and release β-lactamase when needed. It is a devastating defense because it is so general, targeting the common structural motif in all of the many β-lactam antibiotics.

The interdisciplinary team also showed that the antimicrobial effectiveness of the four β-lactams studied in detail was enhanced by the polymer. They prepared a cobaltocenium metallopolymer that greatly slowed the destructiveness of β-lactamase on a model β-lactam molecule (nitrocefin). The enhancement was modest against two strains, but very pronounced with the hospital-associated strain of MRSA (HA-MRSA). The four antibiotics penicillin-G, amoxicillin, ampicillin, and cefazolin, were protected from β-lactamase hydrolysis via the formation of unique ion-pairs between their carboxylate anions and cationic cobaltocenium moieties.

The study was published on March 17, 2014, in the Journal of the American Chemical Society.

Related Links:

University of South Carolina



Print article

Channels

Genomics/Proteomics

view channel
Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).

Statins May Help Block Transmission of Lyme Disease

A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease. Lyme disease... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel

Huge Modifiable Biomedical Database to Be Available on the Wikidata Site

Genome researchers are exploiting the power of the open Internet community Wikipedia database to create a comprehensive resource for geneticists, molecular biologists, and other interested life scientists. While efficiency in generating scientific data improves almost daily, applying meaningful relationships between... Read more

Business

view channel

European Biotech Agreement to Promote Antigen-Drug Conjugation Technology

Two European biotech companies have joined forces to exploit and commercialize an innovative, site-specific ADC (antigen-drug conjugate) conjugation technology. ProBioGen (Berlin, Germany), a company specializing in the development and manufacture of complex glycoproteins and Eucodis Bioscience (Vienna, Austria), a... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.